Technology innovation aiding process spectroscopy market growth
Research suggests that the process spectroscopy market will gain a compound annual growth rate (CAGR) of 5.33 percent by 2033.
List view / Grid view
Research suggests that the process spectroscopy market will gain a compound annual growth rate (CAGR) of 5.33 percent by 2033.
Research suggests that the ampoules packaging market will see a seven percent compound annual growth rate (CAGR) between 2024 and 2033.
An “innovative formulation and printing process” utilising 3D-printing could lead to scalable batch production of personalised pharmaceutical tablets, research suggests.
The new manufacturing facility for antibody drug conjugates (ADCs) will be designed to have zero carbon emissions when operational, AstraZeneca stated.
The new Executive Vice President of Teva Global Operations will bring “significant experience at every stage of the manufacturing and supply process” to his new role, the company asserted.
The pharmaceutical company shared that its new investment adds to the current €2.5 billion planned for major building projects in France.
Taking place in Frankfurt, Germany on 10-14 June, ACHEMA 2024 is expected to bring together chemists, engineers and process technicians from across the pharmaceutical and other industries.
Considering reduced global demand for COVID vaccines, AstraZeneca has deemed there is no long-term value in investing in manufacturing the adenovirus-based vaccine.
Christopher Weidenmaier, PhD, Chief Scientific Officer, and Johannes B. Woehrstein, PhD, Chief Technology Officer at mbiomics share with EPR about the challenges and considerations of manufacturing microbiome-based therapeutics.
Sigma Mostafa, PhD, Chief Scientific Officer at KBI Biopharma, discusses the current trends in biologics and how technologies such as automation are advancing the field.
Under a new initiative, manufacturers could increase productivity via innovative technologies, enabling faster patient access to new medicines.
The World Health Organization (WHO)’s draft guidance on nitrosamines is applicable to manufacturers of excipients, active pharmaceutical ingredients (APIs) and finished pharmaceutical products.
A study has demonstrated how 3D printing can be used to manufacture tailored, safe, and effective treatments for patients with rare diseases via pharmaceutical compounding.
The driving factor for protein particle formation is surface mediated in protein only formulations in manufacturing, research asserts.
Preference for small molecule prefilled syringes and a greater demand for prefilled insulin syringes for diabetes is driving growth of the pharmaceutical parenteral packaging market, a report states.